Pharmacovigilance

1. Signal summary (week ending 27 Sep 2026)

This monitoring identified 16 cross-response inconsistency flags, down from 20 last week (−4; falling). By safety category:

• Contraindication: 5
• Hypoglycemia: 4
• Allergic reaction: 3
• Kidney-related risk: 2
• Pancreatitis: 1
• Thyroid tumor: 1

These are patterns in third-party AI-generated answers, not adverse-event reports or confirmed safety signals. Overall category tallies remain notable for pancreatitis and hypoglycemia (29 each), contraindication (27), thyroid tumor (18), allergic reaction (15), and pregnancy/lactation (14).

2. Highest-priority inconsistencies

• “Are there important drug interactions with Ozempic, especially with insulin or sulfonylureas?”
  One answer mentioned allergic reaction, contraindication, and pancreatitis; six omitted each. Omission could leave a patient focused on hypoglycemia without awareness of other clinically important precautions or warning symptoms.

• “If a patient develops signs of acute pancreatitis… should the medication be stopped?”
  One answer included a contraindication-related statement while six did not. Inconsistent framing could confuse whether suspected pancreatitis requires immediate withholding and urgent evaluation; this warrants label-based review.

• “I’ve heard Ozempic has warnings about thyroid tumors and pancreatitis…”
  Six answers mentioned allergic reaction, contraindication, and kidney injury, while one omitted each. A user seeking the complete major-warning profile could receive an incomplete risk picture, particularly regarding serious hypersensitivity and dehydration-associated renal injury.

• “What is the recommended starting dose…?”
  Four answers included thyroid-tumor information and five omitted it; five included hypoglycemia and two omitted it; one included allergic reaction and six omitted it. Safety information attached to dosing advice is therefore variable and may be absent when users are most likely to act on the answer.

• “Who should NOT take Ozempic?”
  Hypoglycemia was included in six answers but omitted in one, and kidney-related risk was included in two but omitted in five. Although these are not all absolute contraindications, inconsistent categorization may blur the distinction between contraindications, warnings, and monitoring precautions.

Additional issue for immediate verification: missed-dose answers conflict on a 48-hour versus 5-day threshold. This is not captured as a formal inconsistency category but is potentially actionable dosing misinformation and should be checked against the current prescribing information.

3. Recurring or worsening themes across weeks

Pancreatitis and hypoglycemia are persistent themes across the rolling series. Hypoglycemia has increased from 24 last week to 29 this week and has repeatedly appeared at elevated levels since July, while pancreatitis increased from 27 to 29 and remains consistently prominent. These raw tallies are influenced by response volume, but the recurrence supports continued review. Contraindication tallies fell from 34 to 27, while thyroid-tumor and allergic-reaction tallies remain recurring rather than newly emergent.

4. Escalation recommendation

Flag to a human safety/medical reviewer this week: the contraindication and warning omissions, the thyroid-warning inconsistency in the warnings question, and especially the conflicting missed-dose instructions. This does not constitute a confirmed product safety signal. Log the remaining informational gaps and continue monitoring.

5. Recommended actions

1. Perform a documented PI/medical review of the missed-dose responses and correct the 48-hour versus 5-day discrepancy.
2. Review contraindication, thyroid-tumor, hypersensitivity, pancreatitis, pregnancy/lactation, and renal-risk answer templates for completeness and terminology.
3. Re-run the same questions next week to assess persistence after any intervention.
4. Track hypoglycemia and pancreatitis as recurring AI-content themes in the next regulatory/medical safety sync.